CIDEB: A Potential Drug Target and Biomarker for Cell Death Activator CIDE-B (ISO Form 1)

Target Name: CIDEB

NCBI ID: G27141

CIDEB

CIDEB: A Potential Drug Target and Biomarker for Cell Death Activator CIDE-B (ISO Form 1)

Introduction

Apoptosis, the process of natural cell death, is a crucial mechanism for tissue homeostasis and development. However, imbalances in apoptosis have been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The cell death activator CIDE-B (ISO Form 1) has been identified as a potential drug target and biomarker for several diseases. In this article, we will discuss the molecular mechanisms of CIDE-B and its potential as a drug target.

Molecular Mechanisms of CIDE-B

CIDE-B is a non-coding RNA molecule that has been shown to play a critical role in cell apoptosis. It is expressed in a variety of tissues and cells and is involved in the regulation of cell survival and death. CIDE-B functions as a negative regulator of the B-cell receptor (BCR), a surface receptor that plays a crucial role in B-cell development and activation.

CIDE-B has been shown to regulate the BCR by interacting with its extracellular domain. This interaction allows CIDE-B to inhibit the tyrosine phosphorylation of BCR, which is necessary for B-cell receptor signaling. As a result, CIDE-B has been shown to prevent BCR-mediated signaling events that promote B-cell proliferation and survival.

CIDE-B has also been shown to regulate apoptosis by affecting the expression of genes involved in cell death. For example, it has been shown to inhibit the expression of genes involved in the production of pro-apoptotic transcription factors, such as Bax and p53 . This inhibition of pro-apoptotic genes allows CIDE-B to promote apoptosis in response to B-cell receptor signaling.

Drug Targeting Strategies for CIDE-B

The potential drug targeting of CIDE-B is based on its role as a negative regulator of BCR signaling and its involvement in apoptosis. Several drug development strategies have been proposed to target CIDE-B and inhibit its function as a drug target.

1. Small Molecule Antibodies: One approach to drug targeting CIDE-B is to develop small molecule antibodies that specifically bind to CIDE-B. These antibodies can be used to block CIDE-B function in cell culture models or in animal models of disease.

2. RNA Interference: Another approach to drug targeting CIDE-B is to use RNA interference (RNAi) to knockdown CIDE-B in target cells. This approach can be used to identify potential drug targets or to modulate CIDE-B function in cell culture models or in animal models of disease.

3. DNA aptamer: DNA aptamer is a protein that can bind to a specific DNA sequence. By designing specific DNA aptamers, it can bind to CIDE-B and inhibit its function. This approach could be used to treat CIDE-B-related diseases.

4. Gene editing technology: Another approach to drug targeting CIDE-B is to use CRISPR/Cas9 gene editing technology to knockdown or upregulate CIDE-B in target cells. This approach can be used to identify potential drug targets or to modulate CIDE-B function in cell culture models or in animal models of disease.

Conclusion

CIDE-B is a non-coding RNA molecule that has been shown to play a critical role in cell apoptosis. Its function as a negative regulator of B-cell receptor signaling and its involvement in apoptosis make it an attractive drug target. Several drug development Strategies have been proposed to target CIDE-B, including small molecule antibodies, RNA interference, DNA aptamers, and gene editing technology. Further studies are needed to determine the efficacy and safety of these strategies

Protein Name: Cell Death Inducing DFFA Like Effector B

Functions: Lipid transferase specifically expressed in hepatocytes, which promotes unilocular lipid droplet formation by mediating lipid droplet fusion (PubMed:35939579). Lipid droplet fusion promotes their enlargement, restricting lipolysis and favoring lipid storage (PubMed:35939579). Localizes on the lipid droplet surface, at focal contact sites between lipid droplets, and mediates atypical lipid droplet fusion by promoting directional net neutral lipid transfer from the smaller to larger lipid droplets (By similarity). The transfer direction may be driven by the internal pressure difference between the contacting lipid droplet pair (By similarity). Promotes lipid exchange and lipid droplet fusion in both small and large lipid droplet-containing hepatocytes (By similarity). In addition to its role in lipid droplet fusion, also involved in cytoplasmic vesicle biogenesis and transport (By similarity). Required for very-low-density lipoprotein (VLDL) lipidation and maturation (By similarity). Probably involved in the biogenesis of VLDL transport vesicles by forming a COPII vesicle coat and facilitating the formation of endoplasmic reticulum-derived large vesicles (By similarity). Also involved in sterol-regulated export of the SCAP-SREBP complex, composed of SCAP, SREBF1/SREBP1 and SREBF2/SREBP2, by promoting loading of SCAP-SREBP into COPII vesicles (By similarity). May also activate apoptosis (PubMed:10619428)

The "CIDEB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIDEB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets